The antibodies update: Promise, progress, and lessons learned

The antibodies update: Promise, progress, and lessons learned

Thursday, October 1, 2020 9:15 PM to 10:00 PM · 45 min. (Africa/Abidjan)
October 1

Information

Whether it’s testing, treatment, or vaccine development, antibodies are at the center of the research community’s race to put coronavirus behind us. Our distinguished panel in conversation about the latest antibody developments in the fight against COVID-19. We'll discuss breakthroughs, bottlenecks, tech and regulatory hurdles, and the challenges to scale-up.
Twist BioscienceTwist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research. Follow us on Twitter | Facebook">Facebook | LinkedIn | YouTube">YouTube 

Registered attendees

Aaron Sato
Aaron Sato
CSOTwist
Aishani Aatresh
Aishani Aatresh
Research Interndistributed bio
Casey Lippmeier
Casey Lippmeier
VP of InnovationConagen

Log in